CVS Health Affirms 2026 Financial Outlook as Turnaround Gains Momentum
CVS Health maintained its 2026 profit targets today after beating quarterly earnings estimates. Growth in pharmacy services helped offset rising medical costs in its insurance segment.
Insights:
CVS Health Corporation announced on February 10, 2026, that it has maintained its full-year 2026 adjusted earnings guidance of $7.00 to $7.20 per share and a revenue projection of at least $400 billion. The company, which operates extensively across the US 
US, reported fourth-quarter results characterized by higher revenue and increased prescription volume. These results and the reiterated guidance serve as a direct signal to investors regarding the progress of the company's stated turnaround and restructuring efforts following a year of operational changes in 2025.
US, reported fourth-quarter results characterized by higher revenue and increased prescription volume. These results and the reiterated guidance serve as a direct signal to investors regarding the progress of the company's stated turnaround and restructuring efforts following a year of operational changes in 2025.Company leadership, including Brian Newman, attributed the improved performance to recent operational changes and strategic asset purchases. CVS Health indicated that these factors have not only stabilized the business but also signaled the possibility of exceeding its established financial targets. The company’s ability to maintain its guidance at such a large scale is being closely monitored by market participants assessing risk and performance in the wake of significant restructuring.
